HOWL — Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 46
- Website: https://werewolftx.com
Latest SEC filings for HOWL
- SCHEDULE 13G — 2026-09-21
- 8-K — 2026-08-21
- 8-K — 2026-08-20
- 8-K — 2026-07-31
- 10-Q — 2026-07-31
- SCHEDULE 13D/A — 2026-07-03
- SCHEDULE 13D/A — 2026-06-26
- SCHEDULE 13D/A — 2026-06-22
- SCHEDULE 13D/A — 2026-06-16
- SCHEDULE 13D/A — 2026-05-14
Latest HOWL news
- — KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome (Zacks Investment Research)
- — Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why (Zacks Investment Research)
- — TGTX Stock Rises 60% in 6 Months: Here's What You Should Know (Zacks Investment Research)
- — Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases (Zacks Investment Research)
- — Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why (zacks.com)
- — New Strong Buy Stocks for October 9th (Zacks Investment Research)
- — New Strong Buy Stocks for October 9th
- — Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts
Educational tool only — not investment advice.